Mauna Kea Technologies SAS represents a set of core values and a corporate philosophy that is deeply rooted in innovation, excellence, and patient-centricity. The company strives to revolutionize medical imaging and diagnostics by developing cutting-edge medical devices and technology solutions. Mauna Kea Technologies SAS is committed to improving patient outcomes by providing physicians with real-time, high-resolution imaging capabilities for a more accurate and precise diagnosis. The company also prioritizes ethical practices, sustainable development, and collaboration with healthcare professionals to advance the field of medical imaging. Mauna Kea Technologies SAS is dedicated to pushing boundaries and constantly striving for excellence in the healthcare industry.

Mauna Kea Technologies SAS is primarily present in several countries and regions globally. It has a significant presence in the United States, particularly in the New York City metropolitan area. In addition, the company operates extensively in Europe, with a strong presence in France, Germany, Italy, Spain, and the United Kingdom. Mauna Kea Technologies SAS also has a growing market share in the Asia-Pacific region, including Australia, China, Japan, and South Korea. With its widespread international presence, Mauna Kea Technologies SAS continues to expand its reach and impact in the field of medical technology and innovative imaging solutions.

Mauna Kea Technologies SAS has achieved several significant milestones throughout its history. The company introduced Cellvizio, a breakthrough endomicroscopy platform, which has transformed the way physicians diagnose and monitor diseases. The technology has gained widespread recognition and has been adopted by renowned medical institutions globally. Furthermore, Mauna Kea Technologies SAS secured regulatory approvals for its innovative products, strengthening its market position and expanding its customer base. The company's dedication to research and development has led to numerous patents and advancements in optical biopsy solutions. Overall, Mauna Kea Technologies SAS has consistently demonstrated its commitment to advancing medical imaging and improving patient care.

Mauna Kea Technologies SAS is a renowned medical technology company specializing in the development and commercialization of innovative optical biopsy products. Founded in 2000, the company has focused on revolutionizing the detection and treatment of cancer and other diseases through its proprietary Cellvizio® platform. Mauna Kea Technologies has successfully integrated high-resolution imaging and miniaturized endomicroscopy into its advanced devices, enabling physicians to perform real-time, in vivo microscopy during standard procedures. With a commitment to improving patient outcomes and advancing medical knowledge, Mauna Kea Technologies SAS continues to drive advancements in optical biopsy technology worldwide. Find out more about Mauna Kea Technologies SAS on our stock website.

The main competitors of Mauna Kea Technologies SAS in the market include companies such as Intuitive Surgical, Medtronic, Olympus Corporation, and Pentax Medical.

Mauna Kea Technologies SAS is primarily active in the medical industry, specifically in the field of innovative medical devices.

The business model of Mauna Kea Technologies SAS revolves around pioneering and delivering innovative endomicroscopy solutions. As a global medical device company, Mauna Kea specializes in developing and commercializing probe-based Confocal Laser Endomicroscopy (pCLE) technology. This enables real-time visualization of tissue at the cellular level during minimally invasive procedures. By combining advanced imaging capabilities with their Cellvizio platform, Mauna Kea enables medical professionals to improve patient care and treatment outcomes. Through strategic partnerships and commercialization efforts, the company aims to leverage its cutting-edge technologies to enhance diagnostic procedures and revolutionize healthcare practices worldwide.

P/E odnos Mauna Kea Technologies iznosi -2,31.

KUV kompanije Mauna Kea Technologies iznosi 1,64.

AlleAktien kvalitativni skor za Mauna Kea Technologies je 2/10.

očekivana Mauna Kea Technologies promet je 11,02 mil. EUR.

Dobit očekivana Mauna Kea Technologies je -7,85 mil. EUR.

Mauna Kea Technologies SAS is a French company that specializes in the development and marketing of medical devices and procedures that provide precise diagnostic and therapeutic solutions for various types of cancer. The company uses its patented technologies to develop applications for endoscopic imaging, fluorescence microscopy, and optical biopsy.

Mauna Kea Technologies isplaćuje dividendu od 0 EUR raspoređenu preko isplata u toku godine.

Dividenda za Mauna Kea Technologies trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Mauna Kea Technologies je FR0010609263.

WKN od Mauna Kea Technologies je A1JCLA.

Oznaka za praćenje akcija kompanije Mauna Kea Technologies je ALMKT.PA.

U poslednjih 12 meseci, Mauna Kea Technologies je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Mauna Kea Technologies će verovatno isplatiti dividendu od 0 EUR.

Dividendski prinos od Mauna Kea Technologies trenutno iznosi .

Mauna Kea Technologies isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Mauna Kea Technologies je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 EUR. To odgovara dividendnom prinosu od 0 %.

Mauna Kea Technologies se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Mauna Kea Technologies od 18. 8. 2024. u iznosu od 0 EUR, morali ste da imate akciju u depou pre Ex-dana 18. 8. 2024..

Isplata poslednje dividende izvršena je 18. 8. 2024..

U godini 2023 kompanija Mauna Kea Technologies je isplatila 0 EUR kao dividende.

Dividende od Mauna Kea Technologies se isplaćuju u EUR.